Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 10/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15760276 | 0.82 | ACKR3 (0.43) | ACKR3IRAK4MALT1 | |
| SCHEMBL15760261 | 0.81 | ACKR3 (0.35) | ACKR3RIPK1 | |
| SCHEMBL15760561 | 0.71 | ACKR3 (0.36) | ACKR3MALT1 | |
| SCHEMBL17697115 | 0.70 | CYP2D6 (0.48) | — | |
| SCHEMBL20021215 | 0.68 | HTR2C (0.45) | ACKR3 | |
| SCHEMBL17687760 | 0.67 | CYP11B2 (0.46) | — | |
| SCHEMBL7324694 | 0.64 | PIK3R1 (0.55) | ACKR3 | |
| SCHEMBL5496661 | 0.64 | HTR2C (0.65) | — | |
| SCHEMBL15760260 | 0.63 | ACKR3 (0.43) | ACKR3MALT1 | |
| SCHEMBL15760247 | 0.63 | ACKR3 (0.48) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20180086766-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783544-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160145259-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9169261-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086766-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | ACKR3 7/4885IRAK4 1667/4885RIPK1 2335/4885 |
| US-20160145259-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | ACKR3 7/4885IRAK4 1667/4885RIPK1 2335/4885 |
| US-11834452-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | ACKR3 7/4885IRAK4 1667/4885RIPK1 2335/4885 |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | ACKR3 7/4885IRAK4 1667/4885RIPK1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.